Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens

Sipuleucel-T, an autologous cellular immunotherapy, was approved to treat metastatic castration-resistant prostate cancer in 2010 in the United States. Treatment with sipuleucel-T primes the immune system to target prostate acid phosphatase, which is expressed by prostate cancer cells, potentially l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kibel, Adam S, Inman, Brant A, Pachynski, Russell K, Vu, Tuyen, Sheikh, Nadeem A, Petrylak, Daniel P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826523/
https://www.ncbi.nlm.nih.gov/pubmed/33630063
http://dx.doi.org/10.1093/jnci/djab025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826523/
https://www.ncbi.nlm.nih.gov/pubmed/33630063
http://dx.doi.org/10.1093/jnci/djab025

Ejemplares similares